Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 65 entries
Sorted by: Best Match Show Resources per page
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.

Clinical genitourinary cancer

Heinrich D, Bektic J, Bergman AM, Caffo O, Cathomas R, Chi KN, Daugaard G, Keizman D, Kindblom J, Kramer G, Olmos D, Omlin A, Sridhar SS, Tucci M, van Oort I, Nilsson S.
PMID: 29079165
Clin Genitourin Cancer. 2017 Sep 06; doi: 10.1016/j.clgc.2017.08.020. Epub 2017 Sep 06.

Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases in the United States and Europe in 2013. This followed a reported overall survival benefit for patients treated with radium-223...

Cite
Heinrich D, Bektic J, Bergman AM, et al. The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2017;doi: 10.1016/j.clgc.2017.08.020.
Heinrich, D., Bektic, J., Bergman, A. M., Caffo, O., Cathomas, R., Chi, K. N., Daugaard, G., Keizman, D., Kindblom, J., Kramer, G., Olmos, D., Omlin, A., Sridhar, S. S., Tucci, M., van Oort, I., & Nilsson, S. (2017). The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. Clinical genitourinary cancer, . https://doi.org/10.1016/j.clgc.2017.08.020
Heinrich, Daniel, et al. "The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer." Clinical genitourinary cancer vol. (2017). doi: https://doi.org/10.1016/j.clgc.2017.08.020
Heinrich D, Bektic J, Bergman AM, Caffo O, Cathomas R, Chi KN, Daugaard G, Keizman D, Kindblom J, Kramer G, Olmos D, Omlin A, Sridhar SS, Tucci M, van Oort I, Nilsson S. The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Sep 06; doi: 10.1016/j.clgc.2017.08.020. Epub 2017 Sep 06. PMID: 29079165.
Copy Download .nbib Format: NLM
Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy.

Journal of clinical medicine

Conteduca V, Caffo O, Scarpi E, Sepe P, Galli L, Fratino L, Maines F, Chiuri VE, Santoni M, Zanardi E, Massari F, Toma I, Lolli C, Schepisi G, Sbrana A, Kinspergher S, Cursano MC, Casadei C, Modonesi C, Santini D, Procopio G, De Giorgi U.
PMID: 32580478
J Clin Med. 2020 Jun 22;9(6). doi: 10.3390/jcm9061950.

Androgen deprivation therapy (ADT) is a cornerstone of treatment for prostate cancer and, in recent years, androgen receptor (AR)-targeted therapies (abiraterone and enzalutamide) have both been used for the treatment of castration-resistant prostate cancer (CRPC). In our study, we...

Cite
Conteduca V, Caffo O, Scarpi E, et al. Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. J Clin Med. 2020;9(6)doi: 10.3390/jcm9061950.
Conteduca, V., Caffo, O., Scarpi, E., Sepe, P., Galli, L., Fratino, L., Maines, F., Chiuri, V. E., Santoni, M., Zanardi, E., Massari, F., Toma, I., Lolli, C., Schepisi, G., Sbrana, A., Kinspergher, S., Cursano, M. C., Casadei, C., Modonesi, C., Santini, D., Procopio, G., & De Giorgi, U. (2020). Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. Journal of clinical medicine, 9(6), . https://doi.org/10.3390/jcm9061950
Conteduca, Vincenza, et al. "Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy." Journal of clinical medicine vol. 9,6 (2020). doi: https://doi.org/10.3390/jcm9061950
Conteduca V, Caffo O, Scarpi E, Sepe P, Galli L, Fratino L, Maines F, Chiuri VE, Santoni M, Zanardi E, Massari F, Toma I, Lolli C, Schepisi G, Sbrana A, Kinspergher S, Cursano MC, Casadei C, Modonesi C, Santini D, Procopio G, De Giorgi U. Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. J Clin Med. 2020 Jun 22;9(6). doi: 10.3390/jcm9061950. PMID: 32580478; PMCID: PMC7356925.
Copy Download .nbib Format: NLM
Sex and Body Circumferences Associated with Serum Leptin in African American Adults.

Journal of women's health (2002)

Caffo O, Ralston PA, Lemacks JL, Young-Clark I, Wickrama KKAS, Ilich JZ.
PMID: 33661054
J Womens Health (Larchmt). 2021 Dec;30(12):1769-1777. doi: 10.1089/jwh.2020.8820. Epub 2021 Mar 03.

No abstract available.

Cite
Caffo O, Ralston PA, Lemacks JL, et al. Sex and Body Circumferences Associated with Serum Leptin in African American Adults. J Womens Health (Larchmt). 2021;30(12):1769-1777doi: 10.1089/jwh.2020.8820.
Caffo, O., Ralston, P. A., Lemacks, J. L., Young-Clark, I., Wickrama, K. K. A. S., & Ilich, J. Z. (2021). Sex and Body Circumferences Associated with Serum Leptin in African American Adults. Journal of women's health (2002), 30(12), 1769-1777. https://doi.org/10.1089/jwh.2020.8820
Caffo, Olenka, et al. "Sex and Body Circumferences Associated with Serum Leptin in African American Adults." Journal of women's health (2002) vol. 30,12 (2021): 1769-1777. doi: https://doi.org/10.1089/jwh.2020.8820
Caffo O, Ralston PA, Lemacks JL, Young-Clark I, Wickrama KKAS, Ilich JZ. Sex and Body Circumferences Associated with Serum Leptin in African American Adults. J Womens Health (Larchmt). 2021 Dec;30(12):1769-1777. doi: 10.1089/jwh.2020.8820. Epub 2021 Mar 03. PMID: 33661054; PMCID: PMC8721506.
Copy Download .nbib Format: NLM
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak.

Therapeutic advances in urology

Bersanelli M, Buti S, Rizzo M, Cortellini A, Cattrini C, Massari F, Masini C, Vitale MG, Fornarini G, Caffo O, Atzori F, Gatti A, Macrini S, Mucciarini C, Galli L, Morelli F, Stellato M, Fanelli M, Corti F, Zucali PA, Toscani I, Dalla Volta A, Gernone A, Baldessari C, La Torre L, Zara D, Gennari A, Bracarda S, Procopio G, Porta C.
PMID: 34707691
Ther Adv Urol. 2021 Oct 22;13:17562872211054302. doi: 10.1177/17562872211054302. eCollection 2021.

BACKGROUND: Considering the growing genitourinary (GU) cancer population undergoing systemic treatment with immune checkpoint inhibitors (ICIs) in the context of the COVID-19 pandemic, we planned a clinical audit in 24 Italian institutions treating GU malignancies.OBJECTIVE: The primary objective was...

Cite
Bersanelli M, Buti S, Rizzo M, et al. GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. Ther Adv Urol. 2021;13:17562872211054302doi: 10.1177/17562872211054302.
Bersanelli, M., Buti, S., Rizzo, M., Cortellini, A., Cattrini, C., Massari, F., Masini, C., Vitale, M. G., Fornarini, G., Caffo, O., Atzori, F., Gatti, A., Macrini, S., Mucciarini, C., Galli, L., Morelli, F., Stellato, M., Fanelli, M., Corti, F., Zucali, P. A., Toscani, I., Dalla Volta, A., Gernone, A., Baldessari, C., La Torre, L., Zara, D., Gennari, A., Bracarda, S., Procopio, G., & Porta, C. (2021). GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. Therapeutic advances in urology, 1317562872211054302. https://doi.org/10.1177/17562872211054302
Bersanelli, Melissa, et al. "GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak." Therapeutic advances in urology vol. 13 (2021): 17562872211054302. doi: https://doi.org/10.1177/17562872211054302
Bersanelli M, Buti S, Rizzo M, Cortellini A, Cattrini C, Massari F, Masini C, Vitale MG, Fornarini G, Caffo O, Atzori F, Gatti A, Macrini S, Mucciarini C, Galli L, Morelli F, Stellato M, Fanelli M, Corti F, Zucali PA, Toscani I, Dalla Volta A, Gernone A, Baldessari C, La Torre L, Zara D, Gennari A, Bracarda S, Procopio G, Porta C. GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. Ther Adv Urol. 2021 Oct 22;13:17562872211054302. doi: 10.1177/17562872211054302. eCollection 2021. PMID: 34707691; PMCID: PMC8543560.
Copy Download .nbib Format: NLM
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).

Clinical Medicine Insights. Oncology

Bersanelli M, Buti S, Cortellini A, Bandini M, Banna GL, Pederzoli F, Farè E, Raggi D, Giannatempo P, De Giorgi U, Basso U, Losanno T, Santini D, Mucciarini C, Tucci M, Tambaro R, Farnesi A, Caffo O, Veccia A, Naglieri E, Briganti A, Procopio G, Pignata S, Necchi A.
PMID: 34290538
Clin Med Insights Oncol. 2021 Jul 08;15:11795549211021667. doi: 10.1177/11795549211021667. eCollection 2021.

BACKGROUND: Immune checkpoint inhibitors (ICIs) are currently the standard of care for metastatic urothelial cancer (mUC) after the failure of previous platinum-based chemotherapy. The choice of further therapy after ICI progression is a new challenge, and scarce data support...

Cite
Bersanelli M, Buti S, Cortellini A, et al. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). Clin Med Insights Oncol. 2021;15:11795549211021667doi: 10.1177/11795549211021667.
Bersanelli, M., Buti, S., Cortellini, A., Bandini, M., Banna, G. L., Pederzoli, F., Farè, E., Raggi, D., Giannatempo, P., De Giorgi, U., Basso, U., Losanno, T., Santini, D., Mucciarini, C., Tucci, M., Tambaro, R., Farnesi, A., Caffo, O., Veccia, A., Naglieri, E., Briganti, A., Procopio, G., Pignata, S., & Necchi, A. (2021). Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). Clinical Medicine Insights. Oncology, 1511795549211021667. https://doi.org/10.1177/11795549211021667
Bersanelli, Melissa, et al. "Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)." Clinical Medicine Insights. Oncology vol. 15 (2021): 11795549211021667. doi: https://doi.org/10.1177/11795549211021667
Bersanelli M, Buti S, Cortellini A, Bandini M, Banna GL, Pederzoli F, Farè E, Raggi D, Giannatempo P, De Giorgi U, Basso U, Losanno T, Santini D, Mucciarini C, Tucci M, Tambaro R, Farnesi A, Caffo O, Veccia A, Naglieri E, Briganti A, Procopio G, Pignata S, Necchi A. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). Clin Med Insights Oncol. 2021 Jul 08;15:11795549211021667. doi: 10.1177/11795549211021667. eCollection 2021. PMID: 34290538; PMCID: PMC8274126.
Copy Download .nbib Format: NLM
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study.

Targeted oncology

Santoni M, Massari F, Grande E, Procopio G, Matrana MR, Rizzo M, De Giorgi U, Basso U, Milella M, Iacovelli R, Aurilio G, Incorvaia L, Buti S, Caffo O, Fornarini G, Carrozza F, Mollica V, Rizzo A, Farag F, Molina-Cerrillo J, Battelli N.
PMID: 34338966
Target Oncol. 2021 Sep;16(5):625-632. doi: 10.1007/s11523-021-00828-z. Epub 2021 Aug 02.

BACKGROUND: Renal cell carcinoma with sarcomatoid differentiation is a highly aggressive form of kidney cancer.OBJECTIVE: We aimed to analyze the outcomes of patients treated with cabozantinib for metastatic renal cell carcinoma with sarcomatoid features.METHODS: We retrospectively collected data from...

Cite
Santoni M, Massari F, Grande E, et al. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Target Oncol. 2021;16(5):625-632doi: 10.1007/s11523-021-00828-z.
Santoni, M., Massari, F., Grande, E., Procopio, G., Matrana, M. R., Rizzo, M., De Giorgi, U., Basso, U., Milella, M., Iacovelli, R., Aurilio, G., Incorvaia, L., Buti, S., Caffo, O., Fornarini, G., Carrozza, F., Mollica, V., Rizzo, A., Farag, F., Molina-Cerrillo, J., & Battelli, N. (2021). Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Targeted oncology, 16(5), 625-632. https://doi.org/10.1007/s11523-021-00828-z
Santoni, Matteo, et al. "Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study." Targeted oncology vol. 16,5 (2021): 625-632. doi: https://doi.org/10.1007/s11523-021-00828-z
Santoni M, Massari F, Grande E, Procopio G, Matrana MR, Rizzo M, De Giorgi U, Basso U, Milella M, Iacovelli R, Aurilio G, Incorvaia L, Buti S, Caffo O, Fornarini G, Carrozza F, Mollica V, Rizzo A, Farag F, Molina-Cerrillo J, Battelli N. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Target Oncol. 2021 Sep;16(5):625-632. doi: 10.1007/s11523-021-00828-z. Epub 2021 Aug 02. PMID: 34338966.
Copy Download .nbib Format: NLM
The .

Assessment

Lopez A, Caffò AO, Tinella L, Bosco A.
PMID: 34794332
Assessment. 2021 Nov 18;10731911211058688. doi: 10.1177/10731911211058688. Epub 2021 Nov 18.

Despite great interest in Mind Wandering, a fully validated questionnaire has been lacking. The Four Factors of Mind Wandering (4FMW) Questionnaire, presented here, meets this demand. First, 80 items were judged for content validity by two panels of experts....

Cite
Lopez A, Caffò AO, Tinella L, et al. The . Assessment. 2021;10731911211058688doi: 10.1177/10731911211058688.
Lopez, A., Caffò, A. O., Tinella, L., & Bosco, A. (2021). The . Assessment, 10731911211058688. https://doi.org/10.1177/10731911211058688
Lopez, Antonella, et al. "The ." Assessment vol. (2021): 10731911211058688. doi: https://doi.org/10.1177/10731911211058688
Lopez A, Caffò AO, Tinella L, Bosco A. The . Assessment. 2021 Nov 18;10731911211058688. doi: 10.1177/10731911211058688. Epub 2021 Nov 18. PMID: 34794332.
Copy Download .nbib Format: NLM
Resilience in pregnant women with pre-gestational diabetes during COVID-19 pandemic: the experience of the Papa Giovanni XXIII Hospital in Bergamo, Italy.

Acta diabetologica

Dodesini AR, Caffi A, Spada MS, Trevisan R.
PMID: 33237433
Acta Diabetol. 2021 Mar;58(3):397-399. doi: 10.1007/s00592-020-01640-3. Epub 2020 Nov 25.

No abstract available.

Cite
Dodesini AR, Caffi A, Spada MS, et al. Resilience in pregnant women with pre-gestational diabetes during COVID-19 pandemic: the experience of the Papa Giovanni XXIII Hospital in Bergamo, Italy. Acta Diabetol. 2020;58(3):397-399doi: 10.1007/s00592-020-01640-3.
Dodesini, A. R., Caffi, A., Spada, M. S., & Trevisan, R. (2021). Resilience in pregnant women with pre-gestational diabetes during COVID-19 pandemic: the experience of the Papa Giovanni XXIII Hospital in Bergamo, Italy. Acta diabetologica, 58(3), 397-399. https://doi.org/10.1007/s00592-020-01640-3
Dodesini, Alessandro Roberto, et al. "Resilience in pregnant women with pre-gestational diabetes during COVID-19 pandemic: the experience of the Papa Giovanni XXIII Hospital in Bergamo, Italy." Acta diabetologica vol. 58,3 (2021): 397-399. doi: https://doi.org/10.1007/s00592-020-01640-3
Dodesini AR, Caffi A, Spada MS, Trevisan R. Resilience in pregnant women with pre-gestational diabetes during COVID-19 pandemic: the experience of the Papa Giovanni XXIII Hospital in Bergamo, Italy. Acta Diabetol. 2021 Mar;58(3):397-399. doi: 10.1007/s00592-020-01640-3. Epub 2020 Nov 25. PMID: 33237433; PMCID: PMC7686450.
Copy Download .nbib Format: NLM
Equity in Drug Accessibility: The Surprising Case of Treatments for Metastatic Castration-sensitive Prostate Cancer in European Countries.

European urology oncology

Caffo O, Di Maio M.
PMID: 34535420
Eur Urol Oncol. 2021 Dec;4(6):1011-1012. doi: 10.1016/j.euo.2021.08.002. Epub 2021 Sep 15.

No abstract available.

Cite
Caffo O, Di Maio M. Equity in Drug Accessibility: The Surprising Case of Treatments for Metastatic Castration-sensitive Prostate Cancer in European Countries. Eur Urol Oncol. 2021;4(6):1011-1012doi: 10.1016/j.euo.2021.08.002.
Caffo, O., & Di Maio, M. (2021). Equity in Drug Accessibility: The Surprising Case of Treatments for Metastatic Castration-sensitive Prostate Cancer in European Countries. European urology oncology, 4(6), 1011-1012. https://doi.org/10.1016/j.euo.2021.08.002
Caffo, Orazio, and Di Maio, Massimo. "Equity in Drug Accessibility: The Surprising Case of Treatments for Metastatic Castration-sensitive Prostate Cancer in European Countries." European urology oncology vol. 4,6 (2021): 1011-1012. doi: https://doi.org/10.1016/j.euo.2021.08.002
Caffo O, Di Maio M. Equity in Drug Accessibility: The Surprising Case of Treatments for Metastatic Castration-sensitive Prostate Cancer in European Countries. Eur Urol Oncol. 2021 Dec;4(6):1011-1012. doi: 10.1016/j.euo.2021.08.002. Epub 2021 Sep 15. PMID: 34535420.
Copy Download .nbib Format: NLM
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.

World journal of clinical oncology

Buti S, Bersanelli M, Massari F, De Giorgi U, Caffo O, Aurilio G, Basso U, Carteni G, Caserta C, Galli L, Boccardo F, Procopio G, Facchini G, Fornarini G, Berruti A, Fea E, Naglieri E, Petrelli F, Iacovelli R, Porta C, Mosca A.
PMID: 34909398
World J Clin Oncol. 2021 Nov 24;12(11):1037-1046. doi: 10.5306/wjco.v12.i11.1037.

BACKGROUND: Non-clear cell (ncc) metastatic renal-cell carcinoma (RCC) has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell counterpart. New systemic combination therapies have emerged for metastatic RCC (mRCC), but the pivotal...

Cite
Buti S, Bersanelli M, Massari F, et al. First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. World J Clin Oncol. 2021;12(11):1037-1046doi: 10.5306/wjco.v12.i11.1037.
Buti, S., Bersanelli, M., Massari, F., De Giorgi, U., Caffo, O., Aurilio, G., Basso, U., Carteni, G., Caserta, C., Galli, L., Boccardo, F., Procopio, G., Facchini, G., Fornarini, G., Berruti, A., Fea, E., Naglieri, E., Petrelli, F., Iacovelli, R., Porta, C., & Mosca, A. (2021). First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. World journal of clinical oncology, 12(11), 1037-1046. https://doi.org/10.5306/wjco.v12.i11.1037
Buti, Sebastiano, et al. "First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series." World journal of clinical oncology vol. 12,11 (2021): 1037-1046. doi: https://doi.org/10.5306/wjco.v12.i11.1037
Buti S, Bersanelli M, Massari F, De Giorgi U, Caffo O, Aurilio G, Basso U, Carteni G, Caserta C, Galli L, Boccardo F, Procopio G, Facchini G, Fornarini G, Berruti A, Fea E, Naglieri E, Petrelli F, Iacovelli R, Porta C, Mosca A. First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. World J Clin Oncol. 2021 Nov 24;12(11):1037-1046. doi: 10.5306/wjco.v12.i11.1037. PMID: 34909398; PMCID: PMC8641010.
Copy Download .nbib Format: NLM
The Impact of Two MMPI-2-Based Models of Personality in Predicting Driving Behavior. Can Demographic Variables Be Disregarded?.

Brain sciences

Tinella L, Caffò AO, Lopez A, Grattagliano I, Bosco A.
PMID: 33801557
Brain Sci. 2021 Mar 02;11(3). doi: 10.3390/brainsci11030313.

The driver's personality is a key human factor for the assessment of the fitness to drive (FTD), affecting driving decisions and behavior, with consequences on driving safety. No previous study has investigated the effectiveness of Minnesota Multiphasic Personality Inventory...

Cite
Tinella L, Caffò AO, Lopez A, et al. The Impact of Two MMPI-2-Based Models of Personality in Predicting Driving Behavior. Can Demographic Variables Be Disregarded?. Brain Sci. 2021;11(3)doi: 10.3390/brainsci11030313.
Tinella, L., Caffò, A. O., Lopez, A., Grattagliano, I., & Bosco, A. (2021). The Impact of Two MMPI-2-Based Models of Personality in Predicting Driving Behavior. Can Demographic Variables Be Disregarded?. Brain sciences, 11(3), . https://doi.org/10.3390/brainsci11030313
Tinella, Luigi, et al. "The Impact of Two MMPI-2-Based Models of Personality in Predicting Driving Behavior. Can Demographic Variables Be Disregarded?." Brain sciences vol. 11,3 (2021). doi: https://doi.org/10.3390/brainsci11030313
Tinella L, Caffò AO, Lopez A, Grattagliano I, Bosco A. The Impact of Two MMPI-2-Based Models of Personality in Predicting Driving Behavior. Can Demographic Variables Be Disregarded?. Brain Sci. 2021 Mar 02;11(3). doi: 10.3390/brainsci11030313. PMID: 33801557; PMCID: PMC8000114.
Copy Download .nbib Format: NLM
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology

Novello S, Torri V, Grohe C, Kurz S, Serke M, Wehler T, Meyer A, Ladage D, Geissler M, Colantonio I, Cauchi C, Stoelben E, Ceribelli A, Kropf-Sanchen C, Valmadre G, Borra G, Schena M, Morabito A, Santo A, Gregorc V, Chiari R, Reck M, Schmid-Bindert G, Folprecht G, Griesinger F, Follador A, Pedrazzoli P, Bearz A, Caffo O, Dickgreber NJ, Irtelli L, Wiest G, Monica V, Porcu L, Manegold C, Scagliotti GV.
PMID: 34624497
Ann Oncol. 2021 Oct 05; doi: 10.1016/j.annonc.2021.09.017. Epub 2021 Oct 05.

BACKGROUND: Several strategies have been investigated to improve the 4% survival advantage of adjuvant chemotherapy in early-stage non-small-cell lung cancer (NSCLC). In this investigator-initiated study we aimed to evaluate the predictive utility of the messenger RNA (mRNA) expression levels...

Cite
Novello S, Torri V, Grohe C, et al. International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer. Ann Oncol. 2021;doi: 10.1016/j.annonc.2021.09.017.
Novello, S., Torri, V., Grohe, C., Kurz, S., Serke, M., Wehler, T., Meyer, A., Ladage, D., Geissler, M., Colantonio, I., Cauchi, C., Stoelben, E., Ceribelli, A., Kropf-Sanchen, C., Valmadre, G., Borra, G., Schena, M., Morabito, A., Santo, A., Gregorc, V., Chiari, R., Reck, M., Schmid-Bindert, G., Folprecht, G., Griesinger, F., Follador, A., Pedrazzoli, P., Bearz, A., Caffo, O., Dickgreber, N. J., Irtelli, L., Wiest, G., Monica, V., Porcu, L., Manegold, C., & Scagliotti, G. V. (2021). International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, . https://doi.org/10.1016/j.annonc.2021.09.017
Novello, S, et al. "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer." Annals of oncology : official journal of the European Society for Medical Oncology vol. (2021). doi: https://doi.org/10.1016/j.annonc.2021.09.017
Novello S, Torri V, Grohe C, Kurz S, Serke M, Wehler T, Meyer A, Ladage D, Geissler M, Colantonio I, Cauchi C, Stoelben E, Ceribelli A, Kropf-Sanchen C, Valmadre G, Borra G, Schena M, Morabito A, Santo A, Gregorc V, Chiari R, Reck M, Schmid-Bindert G, Folprecht G, Griesinger F, Follador A, Pedrazzoli P, Bearz A, Caffo O, Dickgreber NJ, Irtelli L, Wiest G, Monica V, Porcu L, Manegold C, Scagliotti GV. International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer. Ann Oncol. 2021 Oct 05; doi: 10.1016/j.annonc.2021.09.017. Epub 2021 Oct 05. PMID: 34624497.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 65 entries